 CAMBRIDGE, Mass., Sept. 10, 2021 PRNewswire -- Synlogic, Inc. Nasdaq: SYBX, a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of investigational Synthetic Biotic medicines for the treatment of Phenylketonuria PKU at the Global PKU Patient Meeting, being held virtually September 10-11 th, 2021. 